Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
WILMINGTON, Del., March 28, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Cardiovascular Systems, Inc. (NASDAQ:CSII)?
- Did you purchase your shares between September 12, 2011 and January 21, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Cardiovascular Systems, Inc. (“CSI” or the “Company”) (NASDAQ:CSII) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Central District of California on behalf of all persons or entities that purchased the common stock of CSI between September 12, 2011 and January 21, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than April 12, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of CSI during the Class Period, or purchased shares prior to the Class Period and still hold CSI, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/cardiovascular-systems-inc-csii.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
